{"createdAt":"8/2/2020, 1:17:59 PM","timestamp":1596388679668,"Company ID number":"116","DMX_ISSUER_NAME":"JINYU BIO-TECHNOLOGY CO.,LTD.","DMX_ISSUER_ID":"IID000000002155025","Country of Classification":"CHINA","name":"Jinyu Bio-Technology Co Ltd ","code":"600201","stock_exchange":"Shanghai Stock Exchange","people":[{"id":"金宇生物技术股份有限公司_张翀宇","group":"board","name":"张翀宇","title":"董事长,董事","isMale":true,"age":"66","degree":"硕士","salary":"173.6万","stockAmount":"1854万","description":"张翀宇:男,汉族,1954年出生,中共党员,研究生学历,高级经济师。1976年12月至1993年2月在呼和浩特市金属材料公司工作,历任业务科科长、副经理、总经理兼党总支委员;1993年3月至今在金宇生物技术股份有限公司工作,任董事长兼总裁、党委书记。曾多次被评为内蒙古自治区“新长征突击手”、优秀共产党员、优秀企业家,同时荣获“全国优秀青年企业家”、“自治区劳动模范”等称号,并获得了“全国五一劳动奖章”。1998年当选为市政协常委委员,2002年当选为内蒙古自治区人大代表,2015年荣获“全国劳动模范”称号,2017年荣获“2017发展中国突出贡献奖”。","lastUpdated":"2019-05-22"},{"id":"金宇生物技术股份有限公司_魏学峰","group":"board","name":"魏学峰","title":"副董事长,董事","isMale":true,"age":"58","degree":"博士","salary":"117.3万","stockAmount":"167.7万","description":"魏学峰:男,汉族,1962年出生,中共党员,博士。1985年-2010年历任金宇保灵生物药品有限公司检验班长、监察室副主任、任厂长助理、监察室主任、企管办主任、总工程师、技术总监、营销公司总经理;2011年至今任金宇保灵生物药品有限公司总兽医师、国家工程实验室副主任;2016年5月至今任金宇生物技术股份有限公司副董事长。2016年荣获“国家科学技术进步二等奖”。","lastUpdated":"2019-05-22"},{"id":"金宇生物技术股份有限公司_张竞","group":"board","name":"张竞","title":"职工董事","isMale":false,"age":"37","degree":"硕士","salary":"105.1万","stockAmount":"72.1万","description":"张竞:女,汉族,1983年出生,硕士研究生。英国特许公认会计师公会(ACCA)会员。2008年3月至2015年8月任安永商业咨询服务经理;2015年11月至2016年4月任金宇生物技术股份有限公司总裁助理、企发部经理;2016年5月至今任金宇生物技术股份有限公司董事、副总裁。2015年11月至今任全国工商联十二大代表,第十二届执行委员会委员。","lastUpdated":"2019-05-22"},{"id":"金宇生物技术股份有限公司_王永胜","group":"board","name":"王永胜","title":"董事","isMale":true,"age":"56","degree":"博士","salary":"238.4万","stockAmount":"245.6万","description":"王永胜:男,汉族,1964年出生,中共党员,博士。本科就读于中国农业大学兽医学院,硕士就读于中国农业大学兽医学院,博士毕业于中国农业大学动物科技学院动物繁殖生物学。1988年6月至1993年12月任中国农业出版社编辑;1994年1月至1994年9月任中欧农业技术中心编辑;1997年7月至2013年1月,历任美国辉瑞动物保健品有限公司中国技术服务经理、技术及注册事务经理、全国销售经理、中国总经理、亚太区新兴市场公共事务总监;2013年1月至2014年5月任默沙东(中国)有限公司副总裁、动物保健事业部总经理;2014年5月至今任金宇保灵生物药品有限公司总经理,2014年8月至今担任金宇生物技术股份有限公司副总裁。","lastUpdated":"2019-05-22"},{"id":"金宇生物技术股份有限公司_赵红霞","group":"board","name":"赵红霞","title":"董事","isMale":false,"age":"47","degree":"本科","salary":"13.68万","stockAmount":"-","description":"赵红霞:女,汉族,1973年出生,本科学历,会计师、注册会计师。2001年至2018年任内蒙古农牧药业有限责任公司财务经理;2011年至2015年任新余市元迪投资有限公司董事长;2018年至今任内蒙古金宇生物控股有限公司董事长、总经理。","lastUpdated":"2019-05-22"},{"id":"金宇生物技术股份有限公司_张桂红","group":"board","name":"张桂红","title":"独立董事","isMale":false,"age":"52","degree":"博士","salary":"0.00","stockAmount":"-","description":"张桂红:女,汉族,1968年出生,中共党员,农学博士,华南农业大学兽医学院教授,博士生导师,美国宾夕法尼亚大学医学院博士后,广东省动物源性人兽共患病防控重点实验室主任,国家生猪现代产业技术体系岗位专家。1993年至2002年在东北农业大学动物医学院任教;2002年至今历任华南农业大学兽医学院副教授、教授。曾获“广东省科技进步一等奖”、“农牧渔业丰收二等奖”、“广东省农业科技推广一等奖”等奖项。现任中国畜牧兽医学会畜牧兽医生物技术学分会常务理事、全国动物防疫专家委员会委员、国家兽用药品工程技术研究中心学术委员会生物制品专业委员会委员。","lastUpdated":"2019-05-22"},{"id":"金宇生物技术股份有限公司_刘震国","group":"board","name":"刘震国","title":"独立董事","isMale":true,"age":"48","degree":"硕士","salary":"0.00","stockAmount":"-","description":"刘震国先生,汉族,1972年出生,经济法研究生,工商管理硕士。长期于深圳市地方税务局、国信证券、德恒律师事务所等机构从事法律事务工作。现任德恒律师事务所总部管理合伙人,兼任德恒深圳负责人、管委会主任。广东省优秀律师。曾任深圳市麦达数字股份有限公司(002137)、力合股份有限公司(000532)、银亿股份有限公司(000981)、深圳市农产品股份有限公司(000061)等公司之独立董事。","lastUpdated":"2019-05-22"},{"id":"金宇生物技术股份有限公司_申嫦娥","group":"board","name":"申嫦娥","title":"独立董事","isMale":false,"age":"57","degree":"博士","salary":"0.00","stockAmount":"-","description":"申嫦娥:女,汉族,1963年出生,会计学博士,北京师范大学经济与工商管理学院会计学教授,博士生导师,中国注册会计师。2003年至2010年担任国家税务总局特邀监察员;1987年至2003年在西安交通大学工作;2003年1月至今在北京师范大学经济与工商管理学院工作,期间发表论文50余篇,出版财务管理、国际财务、税务筹划等书籍10余部,主持国家社科基金项目1项,主持省部级课题2项,主持中央高校基本科研业务专项基金1项,两次获得省部级哲学社会科学优秀成果奖。现任沪深上市公司四川天一科技股份有限公司、兴民智通(集团)股份有限公司和上海会畅通讯股份有限公司独立董事,担任非上市公司前海开源基金管理有限公司和北京中关村银行股份有限公司独立董事,方雄国际控股有限公司(中国香港)外部非执行董事。","lastUpdated":"2019-05-22"},{"id":"金宇生物技术股份有限公司_张占福","group":"supervisoryCommittee","name":"张占福","title":"监事会主席","isMale":true,"age":"56","degree":"大专","salary":"22.41万","stockAmount":"19.41万","description":"张占福:男,汉族,1964年出生,中共党员,大专学历,高级政工师。1983年至1988年在兴和县皮革厂工作;1988年至1999年在兴和县炭素总厂任办公室主任、厂长助理;1999年至2005在内蒙古鸿茅实业股份有限公司任办公室主任、行政总监;2005年7月至今在金宇生物技术股份有限公司任党工办主任、工会主席。","lastUpdated":"2019-05-22"},{"id":"金宇生物技术股份有限公司_张晓琳","group":"supervisoryCommittee","name":"张晓琳","title":"监事","isMale":false,"age":"45","degree":"本科","salary":"3.680万","stockAmount":"-","description":"张晓琳:女,汉族,1975年出生,本科学历。2001年至今在内蒙古农牧药业有限责任公司工作。","lastUpdated":"2019-05-22"},{"id":"金宇生物技术股份有限公司_刘国英","group":"supervisoryCommittee","name":"刘国英","title":"职工监事","isMale":false,"age":"52","degree":"硕士","salary":"78.46万","stockAmount":"1.546万","description":"刘国英:女,汉族,1968年出生,硕士。1988年7月至2001年8月,在内蒙古生物药品厂(金宇保灵生物药品有限公司前身)任职技术员、班长、车间主任。2001年8月至2005年12月,在内蒙古生物药品厂任厂长助理、车间主任;2006年1月至2013年12月任金宇保灵生物药品有限公司任质量总监;2014年1月至今任金宇生物技术股份有限公司监事、监事会主席、总裁助理,金宇保灵生物药品有限公司研发总监。2016年荣获“国家科学技术进步二等奖”。","lastUpdated":"2019-04-29"},{"id":"金宇生物技术股份有限公司_张竞","group":"manager","name":"张竞","title":"总裁","isMale":false,"age":"37","degree":"硕士","salary":"105.1万","stockAmount":"72.1万","description":"张竞:女,汉族,1983年出生,硕士研究生。英国特许公认会计师公会(ACCA)会员。2008年3月至2015年8月任安永商业咨询服务经理;2015年11月至2016年4月任金宇生物技术股份有限公司总裁助理、企发部经理;2016年5月至今任金宇生物技术股份有限公司董事、副总裁。2015年11月至今任全国工商联十二大代表,第十二届执行委员会委员。","lastUpdated":"2019-05-22"},{"id":"金宇生物技术股份有限公司_杨钊","group":"manager","name":"杨钊","title":"董事会秘书","isMale":true,"age":"32","degree":"硕士","salary":"36.18万","stockAmount":"-","description":"杨钊:男,汉族,1988年出生,金融学硕士。2015年6月至2017年2月任东兴证券股份有限公司研究所农林牧渔行业研究员;2017年2月至2019年3月任天风证券股份有限公司研究所农林牧渔行业分析师;2019年3月至今在金宇生物技术股份有限公司工作,任战略规划与投资者关系总监。2019年6月获得上海证券交易所上市公司董事会秘书资格证明。","lastUpdated":"2019-08-23"},{"id":"金宇生物技术股份有限公司_王永胜","group":"manager","name":"王永胜","title":"副总裁","isMale":true,"age":"56","degree":"博士","salary":"238.4万","stockAmount":"245.6万","description":"王永胜:男,汉族,1964年出生,中共党员,博士。本科就读于中国农业大学兽医学院,硕士就读于中国农业大学兽医学院,博士毕业于中国农业大学动物科技学院动物繁殖生物学。1988年6月至1993年12月任中国农业出版社编辑;1994年1月至1994年9月任中欧农业技术中心编辑;1997年7月至2013年1月,历任美国辉瑞动物保健品有限公司中国技术服务经理、技术及注册事务经理、全国销售经理、中国总经理、亚太区新兴市场公共事务总监;2013年1月至2014年5月任默沙东(中国)有限公司副总裁、动物保健事业部总经理;2014年5月至今任金宇保灵生物药品有限公司总经理,2014年8月至今担任金宇生物技术股份有限公司副总裁。","lastUpdated":"2019-05-22"},{"id":"金宇生物技术股份有限公司_李荣","group":"manager","name":"李荣","title":"副总裁","isMale":true,"age":"49","degree":"硕士","salary":"74.81万","stockAmount":"70.57万","description":"李荣:男,汉族,1971年出生,硕士,高级兽医师。1994年至2005年,在内蒙古生物药品厂(金宇保灵生物药品有限公司前身)先后任班长、车间副主任、车间主任、生物药品事业部部长助理、生产二部部长;2006年至2013年,任金宇保灵生物药品有限公司副总经理、生产总监;2013年8月至2017年2月,任金宇生物技术股份有限公司总裁助理、技术总监;2017年3月至今任金宇生物技术股份有限公司智能制造负责人,金宇保灵生物药品有限公司董事长、扬州优邦生物药品有限公司董事长。","lastUpdated":"2019-08-23"}],"companyName":"金宇生物技术股份有限公司","province":"内蒙古自治区","englishName":"Jinyu Bio-Technology Co Ltd","industry":"农林牧渔 — 动物保健","website":"www.jinyu.com.cn","mainBusiness":"生物制药","productsName":["生物制药"],"actualController":"","actualControllerSharePercentage":"","registeredCapital":"11.26亿元","employeeAmount":"1427","phone":"86-0471-6539434","location":"内蒙古自治区呼和浩特市土默特左旗经济技术开发区沙尔沁工业园区金宇大街1号","chineseDescription":"金宇生物技术股份有限公司主要从事兽用生物制品的研发、生产与销售，产品种类涵盖猪、禽、反刍和宠物类四大系列100余种动物疫苗。公司获得了“2019中国上市公司金质量奖”、“2019蛋鸡产业替抗突出贡献奖”、“医药工业百强企业”等荣誉奖项。","foundedDate":"1993-03-13","goPublicDate":"1999-01-15","companyHistory":"金宇生物技术股份有限公司（以下简称“公司”或“本公司”）系1992年12月经呼和浩特市体改委以呼体改宏字（1992）4号文批准设立，发起人为呼和浩特市金属材料公司、包头钢铁稀土公司、呼和浩特市立鑫实业开发公司和呼和浩特市租赁公司，以原呼和浩特市金属材料公司为主体改组设立。1999年1月在上海证券交易所上市，现公司的统一社会信用代码为911500001141618816。所属行业为生物药品制造业类。\n　　2018年12月31日,本公司累计发行股本总数1,170,537,440股,注册资本为1,170,537,440.00元,注册地内蒙古自治区呼和浩特市经济技术开发区沙尔沁工业园区金宇大街1号,办公地址内蒙古自治区呼和浩特市鄂尔多斯西街58号。\n　　截至2019年6月30日，本公司累计发行股本总数1,159,655,441股，注册资本1,159,655,441.00元，注册地：内蒙古自治区呼和浩特市经济技术开发区沙尔沁工业园区金宇大街1号，办公地址：内蒙古自治区呼和浩特市鄂尔多斯西街58号。\n　　截至2019年12月31日，本公司累计发行股本总数1,126,240,241股，注册资本为1,126,240,241元。收起▲","shareholders":[{"organizationId":"00008333","holderName":"内蒙古金宇生物控股有限公司","totalShare":"1.22亿","sharePercentage":"10.86%"},{"organizationId":"T000125370","holderName":"香港中央结算有限公司","totalShare":"1.19亿","sharePercentage":"10.61%"},{"organizationId":"T000073058","holderName":"中国证券金融股份有限公司","totalShare":"2687.42万","sharePercentage":"2.39%"},{"organizationId":"","holderName":"上海淳韬投资管理有限公司-淳韵价值一号证券投资私募基金","totalShare":"2635.10万","sharePercentage":"2.34%"},{"organizationId":"","holderName":"张翀宇","totalShare":"1853.82万","sharePercentage":"1.65%"},{"organizationId":"T000280241","holderName":"中央汇金资产管理有限责任公司","totalShare":"1712.47万","sharePercentage":"1.52%"},{"organizationId":"","holderName":"中国农业银行股份有限公司-中证500交易型开放式指数证券投资基金","totalShare":"1118.00万","sharePercentage":"0.99%"},{"organizationId":"","holderName":"全国社保基金四一八组合","totalShare":"1117.04万","sharePercentage":"0.99%"},{"organizationId":"","holderName":"鲁丹丹","totalShare":"1025.88万","sharePercentage":"0.91%"},{"organizationId":"","holderName":"中信证券-中信银行-中信证券红利价值一年持有混合型集合资产管理计划","totalShare":"960.73万","sharePercentage":"0.85%"}],"englishDescription":"JINYU BIO-TECHNOLOGY CO., LTD. formerly INNER MONGOLIA JINYU GROUP CO., LTD, is a China-based company, principally engaged in the research and development, manufacture and sales of veterinary biopharmaceuticals. The Company mainly provides veterinary vaccines. The Company is also engaged in textile processing business, and the provision of property leasing and management activities. The Company also provides energy products.","englishIndustry":"Biotechnology & Drugs","Price to earnings (ttm)":"154.35","Price to sales (ttm)":"28.37","Price to book (mrq)":"6.70","Price to cash flow (ttm)":"--","Total debt to equity (mrq)":"0.84","Lt debt to equity (mrq)":"0.31","Return on investment (ttm)":"4.39","Return on equity (ttm)":"3.73","Income statement":{},"Balance sheet":{"Cash":"0.03","Cash & equivalents":"1,098.45","Short term investments":"672.48","Cash and short term investments":"1,770.96","Accounts receivable - trade, net":"576.25","Total receivables, net":"642.82","Total inventory":"245.29","Prepaid expenses":"24.31","Other current assets, total":"10.17","Total current assets":"2,693.55","Property/plant/equipment, total - gross":"2,233.64","Accumulated depreciation, total":"(513.90)","Property/plant/equipment, total - net":"1,719.74","Goodwill, net":"130.83","Intangibles, net":"519.71","Long term investments":"414.89","Other long term assets, total":"107.16","Total assets":"5,585.88","Accounts payable":"295.24","Accrued expenses":"71.28","Notes payable/short term debt":"11.03","Current port. of  lt debt/capital leases":"25.00","Other current liabilities, total":"145.45","Total current liabilities":"548.00","Long term debt":"15.08","Total long term debt":"15.08","Total debt":"51.11","Deferred income tax":"10.35","Minority interest":"221.82","Other liabilities, total":"143.35","Total liabilities":"938.60","Common stock, total":"1,126.24","Additional paid-in capital":"881.01","Retained earnings (accumulated deficit)":"2,779.89","Treasury stock - common":"(140.00)","Other equity, total":"0.13","Total equity":"4,647.28","Total liabilities & shareholders' equity":"5,585.88","Total common shares outstanding":"1,098.79","Tangible book value per share, common eq":"3.64","Note receivable - long term":"9.80"},"Cash flow":{"Cash receipts":"1,242.33","Cash payments":"(332.85)","Cash taxes paid":"(128.03)","Changes in working capital":"(376.21)","Cash from operating activities":"405.24","Capital expenditures":"(307.36)","Other investing cash flow items, total":"720.47","Cash from investing activities":"413.11","Financing cash flow items":"(480.57)","Total cash dividends paid":"(403.43)","Issuance (retirement) of debt, net":"37.50","Cash from financing activities":"(846.50)","Foreign exchange effects":"0.06","Net change in cash":"(28.09)"},"keyMetrics":{"Price and Volume":{"Price closing or last bid":"29.19","52 Week High":"29.70","52 Week Low":"14.90","Pricing date":"","10 Day Average Trading Volume":"23.21","Market Capitalization":"32,874.95","52 Week High Date":"","52 Week Low Date":"","3 Month Average Trading Volume":"351.87","Beta":"1.38","1 Day Price Change":"1.53","13 Week Price Return (Daily)":"22.08","26 Week Price Return (Daily)":"44.79","5 Day Price Return (Daily)":"11.97","52 Week Price Return (Daily)":"85.45","Year To Date Price Return (Daily)":"55.93","Month to Date Price Return (Daily)":"4.85","Price Relative to S&P500 (4 Week)":"4.76","Price Relative to S&P500 (13 Week)":"5.49","Price Relative to S&P500 (26 Week)":"30.20","Price Relative to S&P500 (52 Week)":"62.97","Price Relative to S&P500 (YTD)":"43.69"},"Per Share Data":{"EPS excl. Extra Items (Annual)":"0.20","EPS excl. Extra Items (TTM)":"0.19","EPS Normalized (Annual)":"0.21","Revenue per Share (Annual)":"1.00","Revenue per Share (TTM)":"1.03","Book Value (Per Share Annual)":"4.23","Book Value (Per Share Quarterly)":"4.36","Tangible Book Value (Per Share Annual)":"3.64","Tangible Book Value (Per Share Quarterly)":"3.76","Cash Per Share (Per Share Annual)":"1.61","Cash Per Share (Per Share Quarterly)":"1.62","Cash Flow (Per Share Annual)":"0.29","Cash Flow (Per Share TTM)":"--","Dividend (Per Share Annual)":"0.06","Dividends (Per Share TTM)":"0.06","EBITD (Per Share TTM)":"0.24","EPS Basic excl. Extra Items (Annual)":"0.20","EPS Basic excl. Extra Items (TTM)":"0.19","EPS incl. Extra Items (Annual)":"0.20","EPS incl. Extra Items (TTM)":"0.19","Free Cash Flow (Per Share TTM)":"-0.15","Dividend (Per Share 5Y)":"0.23"},"Valuation":{"P/E excl. Extra Items (Annual)":"148.72","P/E excl. Extra Items (TTM)":"154.35","P/E Normalized (Annual)":"140.30","Price to sales (Annual)":"29.18","Price to sales (TTM)":"28.37","Price to Tangible Book (Annual)":"8.23","Price to Tangible Book (Quarterly)":"7.96","Price to Free Cash Flow (Per Share Annual)":"--","Price to Cash Flow (Per Share TTM)":"--","Price to Free Cash Flow (Per Share TTM)":"--","Price to Book (Annual)":"6.90","Price to Book (Quarterly)":"6.70","P/E Basic excl. Extra Items (TTM)":"112.73","P/E excl. Extra Items High (TTM)":"112.73","P/E excl. Extra Items Low (TTM)":"21.01","P/E incl. Extra Items (TTM)":"154.35","Net Debt (Interim)":"-1,736.15","Net Debt (Annual)":"-1,719.84","Dividend Yield (5Y)":"1.17","Dividend Yield":"0.21","Current Dividend Yield (TTM)":"0.21"},"Financial Strength":{"Free Cash Flow (Annual)":"-305.55","Current Ratio (Annual)":"4.92","Net Interest coverage (Annual)":"30.34","Long Term Debt/Equity (Annual)":"0.32","Payout Ratio (Annual)":"30.36","Quick Ratio (Annual)":"4.47","Total Debt/Total Equity (Annual)":"1.10","Current EV/Free Cash Flow (Annual)":"--","Current EV/Free Cash Flow (TTM)":"--","Current Ratio (Quarterly)":"4.52","Long Term Debt/Equity (Quarterly)":"0.31","Quick Ratio (Quarterly)":"4.09","Total Debt/Total Equity (Quarterly)":"0.84","Free Cash Flow (TTM)":"-165.11","Net Interest Coverage (TTM)":"19.29","Payout Ratio (TTM)":"31.52"},"Margins":{"Gross Margin (Annual)":"58.73","Gross Margin (TTM)":"60.45","Net Profit Margin % (Annual)":"20.14","Net Profit Margin (TTM)":"19.43","Operating Margin (Annual)":"22.51","Operating Margin (TTM)":"21.63","Pretax Margin (TTM)":"21.51","Pretax Margin (Annual)":"22.50","Operating Margin (5Y)":"45.93","Pretax Margin (5Y)":"46.06","Free Operating Cash Flow/Revenue (5Y)":"1.06","Free Operating Cash Flow/Revenue (TTM)":"-14.25","Gross Margin (5Y)":"73.13","Net Profit Margin (5Y)":"38.57"},"Management Effectiveness":{"Return on Assets (Annual)":"3.81","Return on Equity (TTM)":"3.73","Return on Average Equity (Annual)":"4.57","Return on Average equity (TTM)":"4.30","Return on Investment (Annual)":"4.54","Return on Investment (TTM)":"4.39","Return on Average Assets (5Y)":"13.04","Return on Average Equity (5Y)":"16.09","Return on Investment (5Y)":"15.61","Asset Turnover (Annual)":"0.19","Asset Turnover (TTM)":"0.19","Inventory Turnover (Annual)":"1.67","Inventory Turnover (TTM)":"1.51","Net Income/Employee (Annual)":"157,129.50","Net Income/Employee (TTM)":"163,685.90","Receivables Turnover (Annual)":"1.68","Receivables Turnover (TTM)":"1.52","Revenue/Employee (Annual)":"780,320.10","Revenue/Employee (TTM)":"842,226.60"},"Growth":{"Revenue Growth (Quarterly YoY)":"9.62","Revenue Growth Rate (5Y)":"1.17","EPS Growth (Quarterly YoY)":"-4.62","EPS Growth (TTM YoY)":"-68.06","EPS Growth Rate (5Y)":"-12.96","Dividend Growth Rate (3Y)":"-39.78","Revenue Growth (TTM YoY)":"-30.74","Revenue Growth (Per Share 5Y)":"-0.63","Revenue Growth Rate (3Y)":"-9.44","EPS Growth Rate (3Y)":"-31.39","Book Value Growth Rate (Per Share 5Y)":"21.93","Tangible Book Value Total Equity CAGR (5Y)":"20.54","Capital Spending growth rate 5 year":"8.27","EBITDA CAGR (5Y)":"-6.07","EBITDA Interim CAGR (5Y)":"-12.07","Free Operating Cash Flow CAGR (5Y)":"--","Total Debt CAGR (5Y)":"152.30","Net Profit Margin Growth Rate (5Y)":"-11.85"},"Income Statement":{"Revenue (Annual)":"1,126.78","Revenue (TTM)":"1,158.90","EBITD (Annual)":"382.17","EBITD (TTM)":"264.22","Earnings Before Taxes (Annual)":"253.50","Earnings Before Taxes (TTM)":"249.32","Net Income to Common (Annual)":"221.04","Net Income to Common (TTM)":"212.91","Earnings Before Taxes Normalized (Annual)":"268.34","Net Income Available to Common Normalized (Annual)":"234.32","Diluted Normalized EPS excl. Extra Items (TTM)":"0.19"}}}